Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID Reference, 4th edition, 372 pages

+ the daily Top 10


  Ovarian Neoplasms

  Free Subscription


Articles published in Clin Cancer Res

Retrieve available abstracts of 95 articles:
HTML format



Single Articles


    July 2020
  1. MORONEY JW, Powderly J, Lieu CH, Bendell JC, et al
    Safety and Clinical Activity of Atezolizumab Plus Bevacizumab in Patients with Ovarian Cancer: A Phase Ib Study.
    Clin Cancer Res. 2020 Jul 28. pii: 1078-0432.CCR-20-0477.
    PubMed     Abstract available


  2. OZA AM, Estevez-Diz MDP, Grischke EM, Hall M, et al
    A biomarker-enriched, randomized Phase II trial of adavosertib (AZD1775) plus paclitaxel and carboplatin for women with platinum-sensitive TP53-mutant ovarian cancer.
    Clin Cancer Res. 2020 Jul 1. pii: 1078-0432.CCR-20-0219.
    PubMed     Abstract available


    June 2020
  3. MAY T, Oza AM
    Measurement Tool of Chemotherapy Sensitivity in Advanced Ovarian Cancer.
    Clin Cancer Res. 2020 Jun 29. pii: 1078-0432.CCR-20-1376.
    PubMed     Abstract available


    May 2020
  4. LHEUREUX S, Oaknin A, Garg S, Bruce JP, et al
    EVOLVE: A Multicenter Open-Label Single-Arm Clinical and Translational Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer after PARP Inhibition Progression.
    Clin Cancer Res. 2020 May 22. pii: 1078-0432.CCR-19-4121.
    PubMed     Abstract available


  5. JI JX, Cochrane DR, Tessier-Cloutier B, Chen SY, et al
    Arginine depletion therapy with ADI-PEG20 limits tumor growth in argininosuccinate synthase deficient ovarian cancer, including small cell carcinoma of the ovary, hypercalcemic type.
    Clin Cancer Res. 2020 May 14. pii: 1078-0432.CCR-19-1905.
    PubMed     Abstract available


  6. LAMPERT EJ, Zimmer AS, Padget MR, Cimino-Mathews A, et al
    Combination of PARP inhibitor olaparib, and PD-L1 inhibitor durvalumab, in recurrent ovarian cancer: a proof-of-concept phase 2 study.
    Clin Cancer Res. 2020 May 12. pii: 1078-0432.CCR-20-0056.
    PubMed     Abstract available


    April 2020
  7. LI J, Pan C, Boese AC, Kang J, et al
    DGKA provides platinum resistance in ovarian cancer through activation of cJUN-WEE1 signaling.
    Clin Cancer Res. 2020 Apr 27. pii: 1078-0432.CCR-19-3790.
    PubMed     Abstract available


    March 2020
  8. YOU B, Robelin P, Tod M, Louvet C, et al
    CA-125 ELIMination rate constant K (KELIM) Is A Marker Of Chemosensitivity In Patients With Ovarian Cancer: Results from the Phase II CHIVA trial.
    Clin Cancer Res. 2020 Mar 24. pii: 1078-0432.CCR-20-0054.
    PubMed     Abstract available


    February 2020
  9. HARRIS RS, Serebrenik AA, Argyris P, Jarvis MC, et al
    The DNA cytosine deaminase APOBEC3B is a molecular determinant of platinum responsiveness in clear cell ovarian cancer.
    Clin Cancer Res. 2020 Feb 14. pii: 1078-0432.CCR-19-2786.
    PubMed     Abstract available


    January 2020
  10. ALVAREZ SECORD A, Bell Burdett K, Owzar K, Tritchler D, et al
    Predictive blood-based biomarkers in epithelial ovarian cancer patients treated with carboplatin and paclitaxel with or without bevacizumab: Results from GOG-0218.
    Clin Cancer Res. 2020 Jan 9. pii: 1078-0432.CCR-19-0226.
    PubMed     Abstract available


    December 2019
  11. OZA AM, Matulonis UA, Alvarez Secord A, Nemunaitis J, et al
    A randomized phase 2 trial of epigenetic priming with guadecitabine and carboplatin in platinum-resistant, recurrent ovarian cancer.
    Clin Cancer Res. 2019 Dec 12. pii: 1078-0432.CCR-19-1638.
    PubMed     Abstract available


    October 2019
  12. HANDLEY KF, Sood AK
    A solution to the dilution: The role for biomarkers in advanced ovarian cancer.
    Clin Cancer Res. 2019 Oct 31. pii: 1078-0432.CCR-19-3072.
    PubMed     Abstract available


    September 2019
  13. SHEE K, Wells JD, Ung M, Hampsch RA, et al
    A transcriptionally-definable subgroup of triple-negative breast and ovarian cancer samples shows sensitivity to HSP90 inhibition.
    Clin Cancer Res. 2019 Sep 26. pii: 1078-0432.CCR-18-2213.
    PubMed     Abstract available


  14. GERBER DE, Infante JR, Gordon MS, Goldberg SB, et al
    Phase Ia Study of Anti-NaPi2b Antibody-Drug Conjugate Lifastuzumab Vedotin DNIB0600A in Non-Small Cell Lung Cancer and Platinum-Resistant Ovarian Cancer Patients.
    Clin Cancer Res. 2019 Sep 20. pii: 1078-0432.CCR-18-3965.
    PubMed     Abstract available


  15. HEITZ F, Kommoss S, Tourani R, Grandelis A, et al
    Dilution of molecular-pathologic gene signatures by medically associated factors might prevent prediction of resection status after debulking surgery in patients with advanced ovarian cancer.
    Clin Cancer Res. 2019 Sep 16. pii: 1078-0432.CCR-19-1741.
    PubMed     Abstract available


  16. BONILLA L, Oza AM
    Targeting TGFbeta Pathway in Adult Granulosa Cell Tumor: Opening Pandora's Box?
    Clin Cancer Res. 2019;25:5432-5434.
    PubMed     Abstract available


  17. MAITLAND ML, O'Cearbhaill RE, Gobburu J
    Cancer Clinical Investigators Should Converge with Pharmacometricians.
    Clin Cancer Res. 2019;25:5182-5184.
    PubMed     Abstract available


    August 2019
  18. PARMAR K, Kochupurakkal BS, Lazaro JB, Wang ZC, et al
    The CHK1 Inhibitor Prexasertib Exhibits Monotherapy Activity in High-Grade Serous Ovarian Cancer Models and Sensitizes to PARP inhibition.
    Clin Cancer Res. 2019 Aug 13. pii: 1078-0432.CCR-19-0448.
    PubMed     Abstract available


    July 2019
  19. ISHAK CA, Lheureux S, De Carvalho DD
    DNA methylation as a robust classifier of epithelial ovarian cancer.
    Clin Cancer Res. 2019 Jul 23. pii: 1078-0432.CCR-19-1797.
    PubMed     Abstract available


  20. LI Z, Zhou W, Zhang Y, Sun W, et al
    ERK regulates HIF-1alpha-mediated platinum resistance by directly targeting PHD2 in ovarian cancer.
    Clin Cancer Res. 2019 Jul 8. pii: 1078-0432.CCR-18-4145.
    PubMed     Abstract available


    May 2019
  21. BODELON C, Killian JK, Sampson JN, Anderson WF, et al
    Molecular classification of epithelial ovarian cancer based on methylation profiling: evidence for survival heterogeneity.
    Clin Cancer Res. 2019 May 29. pii: 1078-0432.CCR-18-3720.
    PubMed     Abstract available


  22. FUCIKOVA J, Rakova J, Hensler M, Kasikova L, et al
    TIM-3 dictates functional orientation of the immune infiltrate in ovarian cancer.
    Clin Cancer Res. 2019 May 10. pii: 1078-0432.CCR-18-4175.
    PubMed     Abstract available


  23. TAO JJ, Cangemi NA, Makker V, Cadoo K, et al
    First-in-Human Phase I Study of the Activin A Inhibitor, STM 434, in Patients with Granulosa Cell Ovarian Cancer and Other Advanced Solid Tumors.
    Clin Cancer Res. 2019 May 8. pii: 1078-0432.CCR-19-1065.
    PubMed     Abstract available


    April 2019
  24. KAWAKAMI E, Tabata J, Yanaihara N, Ishikawa T, et al
    Application of Artificial Intelligence for Preoperative Diagnostic and Prognostic Prediction in Epithelial Ovarian Cancer Based on Blood Biomarkers.
    Clin Cancer Res. 2019 Apr 11. pii: 1078-0432.CCR-18-3378.
    PubMed     Abstract available


  25. TAKENAKA M, Kobel M, Garsed DW, Fereday S, et al
    Survival Following Chemotherapy in Ovarian Clear Cell Carcinoma is Not Associated with Pathological Misclassification of Tumor Histotype.
    Clin Cancer Res. 2019 Apr 9. pii: 1078-0432.CCR-18-3691.
    PubMed     Abstract available


  26. COLOMBAN O, Tod M, Leary A, Ray-Coquard I, et al
    Early Modeled Longitudinal CA-125 Kinetics and Survival of Ovarian Cancer Patients: A GINECO AGO MRC CTU Study.
    Clin Cancer Res. 2019 Apr 1. pii: 1078-0432.CCR-18-3335.
    PubMed     Abstract available


    March 2019
  27. BYKOV Y, Zamarin D
    Virus, Vessel, Victory: A Novel Approach to Tumor Killing.
    Clin Cancer Res. 2019;25:1446-1448.
    PubMed     Abstract available


    January 2019
  28. GREENWOOD HE, McCormick PN, Gendron T, Glaser M, et al
    Measurement of tumor antioxidant capacity and prediction of chemotherapy resistance in preclinical models of ovarian cancer by positron emission tomography.
    Clin Cancer Res. 2019 Jan 16. pii: 1078-0432.CCR-18-3423.
    PubMed     Abstract available


    December 2018
  29. BLAGDEN SP, Hamilton AL, Mileshkin L, Wong S, et al
    Phase IB Dose-Escalation and Expansion Study of AKT kinase inhibitor Afuresertib with Carboplatin and Paclitaxel in Recurrent Platinum-Resistant Ovarian Cancer.
    Clin Cancer Res. 2018 Dec 18. pii: 1078-0432.CCR-18-2277.
    PubMed     Abstract available


    October 2018
  30. WU G, Cao L, Zhu J, Tan Z, et al
    Loss of RBMS3 Confers Platinum-resistance in Epithelial Ovarian Cancer via Activation of miR-126-5p/beta-catenin/CBP signaling.
    Clin Cancer Res. 2018 Oct 2. pii: 1078-0432.CCR-18-2554.
    PubMed     Abstract available


    September 2018
  31. MATUSZEWSKA K, Santry LA, Van Vloten JP, Au Yeung A, et al
    Combining Vascular Normalization with an Oncolytic Virus Enhances Immunotherapy in Advanced Stage Ovarian Cancer.
    Clin Cancer Res. 2018 Sep 11. pii: 1078-0432.CCR-18-0220.
    PubMed     Abstract available


    August 2018
  32. PISANIC TR, Cope L, Lin SF, Yen TT, et al
    Methylomic analysis of ovarian cancers identifies tumor-specific alterations readily detectable in early precursor lesions.
    Clin Cancer Res. 2018 Aug 14. pii: 1078-0432.CCR-18-1199.
    PubMed     Abstract available


  33. LHEUREUX S, Tinker AV, Clarke BA, Ghatage P, et al
    A clinical and molecular Phase II trial of oral ENMD-2076 in ovarian clear cell carcinoma (OCCC): A study of the Princess Margaret Phase II Consortium.
    Clin Cancer Res. 2018 Aug 14. pii: 1078-0432.CCR-18-1244.
    PubMed     Abstract available


    July 2018
  34. TOKER A, Nguyen LT, Stone SC, Yang C, et al
    Regulatory T cells in ovarian cancer are characterized by a highly activated phenotype distinct from that in melanoma.
    Clin Cancer Res. 2018 Jul 31. pii: 1078-0432.CCR-18-0554.
    PubMed     Abstract available


  35. MCNEISH IA
    Neoantigens in ovarian cancer: embarrassment of riches or needles in a haystack?
    Clin Cancer Res. 2018 Jul 6. pii: 1078-0432.CCR-18-1731.
    PubMed     Abstract available


  36. BLYUSS O, Burnell M, Ryan A, Gentry-Maharaj A, et al
    Comparison of longitudinal CA125 algorithms as a first line screen for ovarian cancer in the general population.
    Clin Cancer Res. 2018 Jul 3. pii: 1078-0432.CCR-18-0208.
    PubMed     Abstract available


  37. YANG H, Mao W, Rodriguez-Aguayo C, Mangala LS, et al
    Paclitaxel Sensitivity of Ovarian Cancer can be enhanced by knocking down Pairs of Kinases that regulate MAP4 Phosphorylation and Microtubule Stability.
    Clin Cancer Res. 2018 Jul 3. pii: 1078-0432.CCR-18-0504.
    PubMed     Abstract available


  38. CHEN GM, Kannan L, Geistlinger L, Kofia V, et al
    Consensus on Molecular Subtypes of High-grade Serous Ovarian Carcinoma.
    Clin Cancer Res. 2018 Jul 3. pii: 1078-0432.CCR-18-0784.
    PubMed     Abstract available


    June 2018
  39. SIMPKINS F, Jang K, Yoon H, Hew K, et al
    Dual Src and MEK inhibition decreases ovarian cancer growth and targets tumor initiating stem-like cells.
    Clin Cancer Res. 2018 Jun 29. pii: 1078-0432.CCR-17-3697.
    PubMed     Abstract available


  40. KONSTANTINOPOULOS PA, Matulonis UA
    PARP inhibitors in ovarian cancer: a trailblazing and transformative journey.
    Clin Cancer Res. 2018 Jun 5. pii: 1078-0432.CCR-18-1314.
    PubMed     Abstract available


  41. TUMIATI M, Hietanen S, Hynninen J, Pietila E, et al
    A functional homologous recombination assay predicts primary chemotherapy response and long-term survival in ovarian cancer patients.
    Clin Cancer Res. 2018 Jun 1. pii: 1078-0432.CCR-17-3770.
    PubMed     Abstract available


    May 2018
  42. DENIGER DC, Pasetto A, Robbins PF, Gartner JJ, et al
    T-cell responses to TP53 "hotspot" mutations and unique neoantigens expressed by human ovarian cancers.
    Clin Cancer Res. 2018 May 31. pii: 1078-0432.CCR-18-0573.
    PubMed     Abstract available


  43. GRISHAM R, Moore KN, Gordon MS, Harb W, et al
    Phase Ib Study of Binimetinib with Paclitaxel in Patients with Platinum-Resistant Ovarian Cancer: Final Results, Potential Biomarkers, and Extreme Responders.
    Clin Cancer Res. 2018 May 29. pii: 1078-0432.CCR-18-0494.
    PubMed     Abstract available


  44. UUSI-KERTTULA H, Davies JA, Thompson J, Wongthida P, et al
    Ad5NULL-A20 - a tropism-modified, alphavbeta6 integrin-selective oncolytic adenovirus for epithelial ovarian cancer therapies.
    Clin Cancer Res. 2018 May 24. pii: 1078-0432.CCR-18-1089.
    PubMed     Abstract available


  45. MATSUDA T, Leisegang M, Park JH, Ren L, et al
    Induction of Neoantigen-specific Cytotoxic T Cells and Construction of T-cell Receptor-engineered T cells for Ovarian Cancer.
    Clin Cancer Res. 2018 May 2. pii: 1078-0432.CCR-18-0142.
    PubMed     Abstract available


    April 2018
  46. CAUMANNS JJ, Berns K, Wisman GBA, Fehrmann RSN, et al
    Integrative kinome profiling identifies mTORC1/2 inhibition as treatment strategy in ovarian clear cell carcinoma.
    Clin Cancer Res. 2018 Apr 23. pii: 1078-0432.CCR-17-3060.
    PubMed     Abstract available


  47. DI LJ, Hao D, Liu J, Chen M, et al
    Immunogenomic analyses of advanced serous ovarian cancer reveal immune score is a strong prognostic factor and an indicator of chemo-sensitivity.
    Clin Cancer Res. 2018 Apr 16. pii: 1078-0432.CCR-17-3862.
    PubMed     Abstract available


  48. BELUR NAGARAJ A, Kovalenko O, Avelar RA, Joseph P, et al
    Mitotic Exit dysfunction through the deregulation of APC/C characterizes cisplatin resistant state in epithelial ovarian cancer.
    Clin Cancer Res. 2018 Apr 13. pii: 1078-0432.CCR-17-2885.
    PubMed     Abstract available


  49. ISON G, Howie LJ, Amiri-Kordestani L, Zhang L, et al
    FDA Approval Summary: Niraparib for the maintenance treatment of patients with recurrent ovarian cancer in response to platinum-based chemotherapy.
    Clin Cancer Res. 2018 Apr 12. pii: 1078-0432.CCR-18-0042.
    PubMed     Abstract available


  50. PULLIAM N, Fang F, Ozes AR, Tang J, et al
    An Effective Epigenetic-PARP inhibitor Combination Therapy for Breast and Ovarian Cancers Independent of BRCA-mutations.
    Clin Cancer Res. 2018 Apr 3. pii: 1078-0432.CCR-18-0204.
    PubMed     Abstract available


    March 2018
  51. KALLI KR, Block MS, Kasi PM, Erskine CL, et al
    Folate Receptor Alpha Peptide Vaccine generates immunity in Breast and Ovarian Cancer Patients.
    Clin Cancer Res. 2018 Mar 15. pii: 1078-0432.CCR-17-2499.
    PubMed     Abstract available


  52. MATEI D, Ghamande S, Roman LD, Alvarez Secord A, et al
    A Phase 1 Clinical Trial of Guadecitabine and Carboplatin In Platinum-Resistant, Recurrent Ovarian Cancer: Clinical, Pharmacokinetic And Pharmacodynamic Analyses.
    Clin Cancer Res. 2018 Mar 2. pii: 1078-0432.CCR-17-3055.
    PubMed     Abstract available


    February 2018
  53. HUANG YF, Wu YH, Cheng WF, Peng SL, et al
    Vitamin D-Binding Protein Enhances Epithelial Ovarian Cancer Progression by Regulating the Insulin-like Growth Factor-1/Akt Pathway and Vitamin D Receptor Transcription.
    Clin Cancer Res. 2018 Feb 23. pii: 1078-0432.CCR-17-2943.
    PubMed     Abstract available


  54. LANG JD, Hendricks WPD, Orlando KA, Yin H, et al
    Ponatinib shows potent antitumor activity in small cell carcinoma of the ovary hypercalcemic type (SCCOHT) through multi-kinase inhibition.
    Clin Cancer Res. 2018 Feb 9. pii: 1078-0432.CCR-17-1928.
    PubMed     Abstract available


    January 2018
  55. BELLONE S, Buza N, Choi J, Zammataro L, et al
    Exceptional response to pembrolizumab in a metastatic, chemotherapy/radiation resistant ovarian cancer patient harboring a CD274/PD-L1-genetic rearrangement.
    Clin Cancer Res. 2018 Jan 19. pii: 1078-0432.CCR-17-1805.
    PubMed     Abstract available


  56. HARDWICK NR, Frankel P, Ruel C, Kilpatrick J, et al
    p53-reactive T cells are associated with clinical benefit in patients with platinum-resistant epithelial ovarian cancer after treatment with a p53 vaccine and gemcitabine chemotherapy.
    Clin Cancer Res. 2018 Jan 4. pii: 1078-0432.CCR-17-2709.
    PubMed     Abstract available


    December 2017
  57. TUCKER DW, Getchell CR, McCarthy ET, Ohman AW, et al
    Epigenetic Reprogramming Strategies to Reverse Global Loss of 5-Hydroxymethylcytosine, a Prognostic Factor for Poor Survival in High-grade Serous Ovarian Cancer.
    Clin Cancer Res. 2017 Dec 20. pii: 1078-0432.CCR-17-1958.
    PubMed     Abstract available


    November 2017
  58. PENG G, Mills GB
    Surviving ovarian cancer: an affair between defective DNA repair and RB1.
    Clin Cancer Res. 2017 Nov 30. pii: 1078-0432.CCR-17-3022.
    PubMed     Abstract available


  59. NORQUIST BM, Brady MF, Harrell MI, Walsh T, et al
    Mutations in Homologous Recombination Genes and Outcomes in Ovarian Carcinoma Patients in GOG 218: an NRG Oncology/Gynecologic Oncology Group Study.
    Clin Cancer Res. 2017 Nov 30. pii: 1078-0432.CCR-17-1327.
    PubMed     Abstract available


    October 2017
  60. LABIDI-GALY SI, Olivier T, Rodrigues M, Ferraioli D, et al
    Location of mutation in BRCA2 gene and survival in patients with ovarian cancer.
    Clin Cancer Res. 2017 Oct 30. pii: clincanres.2136.2017.
    PubMed     Abstract available


  61. GARSED DW, Alsop K, Fereday S, Emmanuel C, et al
    Homologous Recombination DNA Repair Pathway Disruption and Retinoblastoma Protein Loss are Associated with Exceptional Survival in High-Grade Serous Ovarian Cancer.
    Clin Cancer Res. 2017 Oct 23. pii: clincanres.1621.2017.
    PubMed     Abstract available


  62. KREUZINGER C, Geroldinger A, Smeets D, Braicu EI, et al
    A complex network of tumor microenvironment in human high grade serous ovarian cancer.
    Clin Cancer Res. 2017 Oct 2. pii: clincanres.1159.2017.
    PubMed     Abstract available


    September 2017
  63. COOKE SL, Ennis D, Evers L, Dowson S, et al
    The driver mutational landscape of ovarian squamous cell carcinomas arising in mature cystic teratoma.
    Clin Cancer Res. 2017 Sep 27. pii: clincanres.1789.2017.
    PubMed     Abstract available


  64. HAO D, Li J, Jia S, Meng Y, et al
    Integrated analysis reveals tubal and ovarian originated serous ovarian cancer and predicts differential therapeutic responses.
    Clin Cancer Res. 2017 Sep 22. pii: clincanres.0638.2017.
    PubMed     Abstract available


    August 2017
  65. RAGHAVAN S, Mehta P, Ward MW, Bregenzer ME, et al
    Personalized Medicine Based Approach to Model Patterns of Chemoresistance and Tumor Recurrence Using Ovarian Cancer Stem Cell Spheroids.
    Clin Cancer Res. 2017 Aug 16. pii: clincanres.0133.2017.
    PubMed     Abstract available


  66. LIU J, Agopiantz M, Poupon J, Wu Z, et al
    Neurotensin receptor 1 antagonist SR48692 improves response to carboplatin by enhancing apoptosis and inhibiting drug efflux in ovarian cancer.
    Clin Cancer Res. 2017 Aug 8. pii: clincanres.0861.2017.
    PubMed     Abstract available


  67. CORNELISON R, Dobbin ZC, Katre AA, Jeong DH, et al
    TARGETING RNA-POLYMERASE I IN BOTH CHEMOSENSITIVE AND CHEMORESISTANT POPULATIONS IN EPITHELIAL OVARIAN CANCER.
    Clin Cancer Res. 2017 Aug 4. pii: clincanres.0282.2017.
    PubMed     Abstract available


  68. WEIGELT B, Comino-Mendez I, de Bruijn I, Tian L, et al
    Diverse BRCA1 and BRCA2 Reversion Mutations in Circulating Cell-Free DNA of Therapy-Resistant Breast or Ovarian Cancer.
    Clin Cancer Res. 2017 Aug 1. pii: clincanres.0544.2017.
    PubMed     Abstract available


    July 2017
  69. BALASUBRAMANIAM S, Beaver JA, Horton S, Fernandes LL, et al
    FDA Approval Summary: Rucaparib for the treatment of patients with deleterious BRCA mutation-associated advanced ovarian cancer.
    Clin Cancer Res. 2017 Jul 27. pii: clincanres.1337.2017.
    PubMed     Abstract available


  70. MENDERES G, Bonazzoli E, Bellone S, Black JD, et al
    SYD985, a Novel Duocarmycin-Based HER2-Targeting Antibody-Drug Conjugate, Shows Antitumor Activity in Uterine and Ovarian Carcinosarcoma with HER2/Neu Expression.
    Clin Cancer Res. 2017 Jul 5. pii: clincanres.2862.2016.
    PubMed     Abstract available


    June 2017
  71. YANG WL, Gentry-Maharaj A, Simmons AR, Ryan A, et al
    Elevation of TP53 Autoantibody Prior to CA125 in Preclinical Invasive Epithelial Ovarian Cancer.
    Clin Cancer Res. 2017 Jun 21. pii: clincanres.0284.2017.
    PubMed     Abstract available


  72. HU Q, Hisamatsu T, Hammerle M, Cho MS, et al
    Role of platelet-derived Tgfbeta1 in the progression of ovarian cancer.
    Clin Cancer Res. 2017 Jun 13. pii: clincanres.3272.2016.
    PubMed     Abstract available


    March 2017
  73. LEE JM, Peer CJ, Yu M, Amable L, et al
    Sequence-Specific Pharmacokinetic and Pharmacodynamic Phase I/Ib Study of Olaparib Tablets and Carboplatin in Women's Cancer.
    Clin Cancer Res. 2017;23:1397-1406.
    PubMed     Abstract available


  74. WANG C, Armasu SM, Kalli KR, Maurer MJ, et al
    Pooled clustering of high-grade serous ovarian cancer gene expression leads to novel consensus subtypes associated with survival and surgical outcomes.
    Clin Cancer Res. 2017 Mar 9. pii: clincanres.0246.2017.
    PubMed     Abstract available


  75. KRISTELEIT R, Shapiro GI, Burris HA, Oza AM, et al
    A Phase I-II Study of the Oral Poly(ADP-ribose) Polymerase Inhibitor Rucaparib in Patients with Germline BRCA1/2-mutated Ovarian Carcinoma or Other Solid Tumors.
    Clin Cancer Res. 2017 Mar 6. pii: clincanres.2796.2016.
    PubMed     Abstract available


  76. APELLANIZ-RUIZ M, Tejero H, Inglada-Perez L, Sanchez-Barroso L, et al
    Targeted Sequencing Reveals Low-Frequency Variants in EPHA Genes as Markers of Paclitaxel-Induced Peripheral Neuropathy.
    Clin Cancer Res. 2017;23:1227-1235.
    PubMed     Abstract available


    February 2017
  77. LHEUREUX S, Lai Z, Dougherty BA, Runswick S, et al
    Long-term responders on olaparib maintenance in high-grade serous ovarian cancer: Clinical and molecular characterization.
    Clin Cancer Res. 2017 Feb 21. pii: clincanres.2615.2016.
    PubMed     Abstract available


  78. NG C, Zhang Z, Lee SI, Marques HS, et al
    CT perfusion as an early biomarker of treatment efficacy in advanced ovarian cancer: an ACRIN and GOG study.
    Clin Cancer Res. 2017 Feb 7. pii: clincanres.1859.2016.
    PubMed     Abstract available


  79. KOMMOSS S, Winterhoff B, Oberg A, Konecny GE, et al
    Bevacizumab may differentially improve ovarian cancer outcome in patients with proliferative and mesenchymal molecular subtypes.
    Clin Cancer Res. 2017 Feb 3. pii: clincanres.2196.2016.
    PubMed     Abstract available


    January 2017
  80. SKATES SJ, Greene MH, Buys SS, Mai PL, et al
    Early Detection of Ovarian Cancer using the Risk of Ovarian Cancer Algorithm with Frequent CA125 Testing in Women at Increased Familial Risk - Combined Results from Two Screening Trials.
    Clin Cancer Res. 2017 Jan 31. pii: clincanres.2750.2015.
    PubMed     Abstract available


  81. ANDERSEN CL, Sikora MJ, Boisen MM, Ma T, et al
    Active estrogen receptor-alpha signaling in ovarian cancer models and clinical specimens.
    Clin Cancer Res. 2017 Jan 10. pii: clincanres.1501.2016.
    PubMed     Abstract available


    December 2016
  82. KIM H, George E, Ragland RL, Rafail S, et al
    Targeting the ATR/CHK1 axis with PARP inhibition results in tumor regression in BRCA mutant ovarian cancer models.
    Clin Cancer Res. 2016 Dec 19. pii: clincanres.2273.2016.
    PubMed     Abstract available


  83. CHATTERJEE J, Dai W, Abd Aziz NH, Teo PY, et al
    Clinical use of programmed cell death-1 (PD-1) and its ligand (PD-L1) expression as discriminatory and predictive markers in ovarian cancer.
    Clin Cancer Res. 2016 Dec 16. pii: clincanres.2366.2016.
    PubMed     Abstract available


    November 2016
  84. VANDERSTICHELE A, Busschaert P, Smeets D, Landolfo C, et al
    Chromosomal instability in cell-free DNA as a highly specific biomarker for detection of ovarian cancer in women with adnexal masses.
    Clin Cancer Res. 2016 Nov 14. pii: clincanres.1078.2016.
    PubMed     Abstract available


  85. MARTINI P, Paracchini L, Caratti G, Mello-Grand M, et al
    lncRNAs as novel indicators of patients' prognosis in stage I epithelial ovarian cancer: a retrospective and multicentric study.
    Clin Cancer Res. 2016 Nov 8. pii: clincanres.1402.2016.
    PubMed     Abstract available


    October 2016
  86. BACHMAYR-HEYDA A, Aust S, Auer K, Meier SM, et al
    Integrative Systemic and Local Metabolomics with Impact on Survival in High Grade Serous Ovarian Cancer.
    Clin Cancer Res. 2016 Oct 19. pii: clincanres.1647.2016.
    PubMed     Abstract available


  87. MONK BJ, Facciabene A, Brady WE, Aghajanian C, et al
    Integrative Development of a TLR8 Agonist for Ovarian Cancer Chemo-immunotherapy.
    Clin Cancer Res. 2016 Oct 4. pii: clincanres.1453.2016.
    PubMed     Abstract available


  88. MCCORMICK A, Donoghue P, Dixon M, O'Sullivan R, et al
    Ovarian Cancers Harbour Defects in Non-Homologous End Joining Resulting in Resistance to Rucaparib.
    Clin Cancer Res. 2016 Oct 4. pii: clincanres.0564.2016.
    PubMed     Abstract available


    September 2016
  89. ZHOU J, Alfraidi A, Zhang S, Santiago-O'Farrill J, et al
    A novel compound ARN-3236 inhibits Salt Inducible Kinase 2 and sensitizes ovarian cancer cell lines and xenografts to paclitaxel.
    Clin Cancer Res. 2016 Sep 27. pii: clincanres.1562.2016.
    PubMed     Abstract available


  90. FLANAGAN JM, Wilson A, Koo C, Masrour N, et al
    Platinum-based chemotherapy induces methylation changes in blood DNA associated with overall survival in ovarian cancer patients.
    Clin Cancer Res. 2016 Sep 23. pii: clincanres.1754.2016.
    PubMed     Abstract available


  91. AU-YEUNG G, Lang F, Azar WJ, Mitchell C, et al
    Selective targeting of Cyclin E1 amplified high grade serous ovarian cancer by cyclin-dependent kinase 2 and AKT inhibition.
    Clin Cancer Res. 2016 Sep 23. pii: clincanres.0620.2016.
    PubMed     Abstract available


  92. MARTIGNETTI JA, Chen Y, Camacho C, Silvers TR, et al
    INHIBITION OF THE NUCLEAR EXPORT RECEPTOR XPO1 AS A THERAPEUTIC TARGET FOR PLATINUM RESISTANT OVARIAN CANCER.
    Clin Cancer Res. 2016 Sep 20. pii: clincanres.1333.2016.
    PubMed     Abstract available


    June 2016
  93. MONTFORT A, Pearce OM, Maniati E, Vincent B, et al
    A strong B cell response is part of the immune landscape in human high-grade serous ovarian metastases.
    Clin Cancer Res. 2016 Jun 27. pii: clincanres.0081.2016.
    PubMed     Abstract available


  94. BOHM S, Montfort A, Pearce OM, Topping J, et al
    Neoadjuvant Chemotherapy Modulates the Immune Microenvironment in Metastases of Tubo-Ovarian High-Grade Serous Carcinoma.
    Clin Cancer Res. 2016;22:3025-36.
    PubMed     Abstract available


    July 2015
  95. YANG JY, Werner HM, Li J, Westin SN, et al
    Integrative Protein-Based Prognostic Model for Early Stage Endometrioid Endometrial Cancer.
    Clin Cancer Res. 2015 Jul 29. pii: clincanres.0104.2015.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Ovarian Neoplasms is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: